drugset / Trial / NCT02480686

Neutrino Regimen for Treatment-experienced HCV GT1 Patients

NCT02480686

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of NEUTRINO regimen in Chinese chronic HCV genotype 1b treatment-experienced patients.

Timeline

Start
2015-01
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2a Protein / enzyme biologic 180 ug Subcutaneous
Subject Ribavirin Small molecule 1000 mg Oral
Subject Ribavirin Small molecule 1200 mg Oral
Subject Sofosbuvir Small molecule 400 mg Oral